Human anti-SARS-CoV-2 broad-spectrum neutralizing monoclonal antibody and application thereof

By developing broad-spectrum neutralizing monoclonal antibodies with unique CDR regions, the problem of existing antibodies' neutralization ability to the Omicron variant strain has been solved, and efficient neutralization of a variety of novel coronavirus variants has been achieved, suitable for COVID-19- 19 prevention and treatment.

CN118978589AActive Publication Date: 2024-11-19THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE +1

Patent Information

Application Number
CN202411411349.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-10
Publication Date
2024-11-19
Estimated Expiration
2044-10-10

AI Technical Summary

Technical Problem

The existing antibodies have significantly reduced the neutralization ability of the Omicron mutant strain of the novel coronavirus, or even completely failed, resulting in failure in front of the mutant strain and unable to effectively prevent the virus from escaping immune.

Method used

A human broad-spectrum neutralizing monoclonal antibody was developed. The antibody with a unique CDR region was obtained by screening through single B-cell flow sorting-antibody gene amplification paired expression technology, which can effectively neutralize SARS-CoV-2 Various novel coronavirus mutations including WT, OmicronBA.5, OmicronXBB.1.5, OmicronEG.5, OmicronJN.1, and OmicronKP.2.

Benefits of technology

This antibody shows high efficiency and neutralization ability to a variety of novel coronavirus variants, with an IC50 value of less than 0.07 μg/mL. It is suitable for emergency prevention and treatment drugs for COVID-19, and has full humanization, high expression and good stability. , suitable for industrial applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978589A_ABST
    Figure CN118978589A_ABST
Patent Text Reader

Abstract

The invention discloses a human-derived monoclonal neutralizing antibody for resisting SARS-COV-2 virus, which is obtained by screening through a single B cell flow sorting-antibody gene amplification pairing expression technology, has a unique CDR region, can be specifically combined with SARS-COV-2 and can effectively neutralize SARS-CoV-2 wild strains and Omicron variant strains such as OmicroBA.5, OmicroXBB.1, OmicroEG.5, OmicroJN.1, OmicroKP.2 and the like, IC50 is lower than 0.1 mu g / mL, and the neutralizing antibody has the advantages of high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, high specificity, the broad-spectrum virus neutralizing activity is realized. The invention also relates to application of the antibody in preparation of a novel coronavirus disease treatment or prevention drug and a detection reagent. The antibody has the characteristics of full humanization, high expression and good stability, and is suitable for industrialization.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention discloses a polypeptide, and more specifically, the present invention discloses an antibody. Background Art

[0002] The new coronavirus (SARS-CoV-2, also known as 2019-nCoV) is a type of positive-strand RNA virus, belonging to the ß genus of the coronavirus family. It encodes four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N), 16 non-structural proteins, and 5-8 auxiliary proteins. SARS-CoV-2 uses the S protein on the surface of the virus and the host cell receptor-angiotensin converting enzyme II (ACE2) to enter the cell. The S protein is divided into two functional units, namely S1 and S2 protein subunits, according to the protein structure and function. S1 can be divided into NTD (N-terminal domain) and RBD (Receptor binding site). The RBD region is about 240 amino acids long and mainly binds to the host cell receptor. S2 plays a role in the fusion of the virus and the cell membrane. According to existing reports, neutralizing antibodies mainly act on the RBD region. The antibody binds to the RBD, hindering the binding of RBD to ACE2, thereby preventing the virus from infecting cells.

[0003] At present, there are reports on the isolation of novel coronavirus neutralizing antibodies at home and abroad. Using single cell sorting and deep sequencing of antibody genomes, a group of human monoclonal antibodies targeting RBD have been isolated, such as LYCoV555, REGN-COV2, TY027, CT-P59, JS016, BRII-196, BRII-198 and SCTA01. These antibodies have shown strong in vitro neutralizing activity and good therapeutic effects in transgenic mice expressing ACE2, which can significantly reduce the viral load in the lungs of mice. However, SARS-CoV-2 is constantly mutating. Once infected with a virus with a mutated neutralizing epitope, the existing neutralizing antibodies will no longer have a neutralizing effect. In particular, since the rapid prevalence of the Omicron strain, variants such as OmicronBA.5, OmicronXBB.1.5, OmicronEG.5, OmicronJN.1, and OmicronKP.2 have been produced, among which OmicronJN.1 is the current main prevalent strain in my country, and OmicronKP.2 was listed as a "variant that needs to be monitored" by the World Health Organization on May 3, 2024. The neutralization ability of the existing monoclonal antibodies on the market against the Omicron variant has been greatly reduced, or even completely ineffective. Therefore, it is necessary to isolate more potent broad-spectrum neutralizing antibodies as alternatives to more effectively avoid immune escape of the virus. The object of the present invention is to provide an anti-new coronavirus monoclonal antibody with a broad-spectrum high-neutralizing activity, and on this basis, to provide the use of the anti-new coronavirus monoclonal antibody with a high-neutralizing activity in the preparation of a novel coronavirus infection therapeutic drug and a diagnostic kit. Summary of the invention

[0004] Based on the above invention objectives, the present invention first provides a human anti-novel coronavirus broad-spectrum neutralizing monoclonal antibody, the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region and CDR1, CDR2 and CDR3 of the light chain variable region of the antibody are as follows: (1) positions 26-35, 53-59 and 98-112 of SEQ ID NO.1 and positions 26-34, 52-54 and 91-103 of SEQ ID NO.3; or (2) positions 26-33, 51-57 and 96-106 of SEQ ID NO.5 and positions 27-32, 50-52 and 89-96 of SEQ ID NO.7; or (3) Positions 26-35, 53-59 and 98-111 of SEQ ID NO.9 and positions 27-32, 50-52 and 89-95 of SEQ ID NO.11.

[0005] In a preferred embodiment, the amino acid sequences of the heavy chain variable region and the light chain variable region of the antibody are respectively as follows: (1) SEQ ID NO.1 and SEQ ID NO.3. The antibody having this technical solution is named “LY-2” in the present invention; or (2) SEQ ID NO.5 and SEQ ID NO.7. The antibody having this technical solution is named “LY-3” in the present invention; or (3) SEQ ID NO.9 and SEQ ID NO.11. In the present invention, an antibody having a specific technical solution of the amino acid sequence of the heavy chain variable region and the light chain variable region is named "LY-7".

[0006] In a more preferred embodiment, the amino acid sequence of the heavy chain constant region of the antibody is as shown in SEQ ID NO.13, and the amino acid sequence of the light chain constant region is as shown in SEQ ID NO.15 (kappa chain) or SEQ ID NO.17 (lambda chain).

[0007] Secondly, the present invention also provides a polynucleotide encoding the above-mentioned human anti-novel coronavirus broad-spectrum neutralizing monoclonal antibody, and the polynucleotide encoding the heavy chain variable region of the antibody and the polynucleotide encoding the light chain variable region of the antibody are respectively as follows: (1) SEQ ID NO.2 and SEQ ID NO.4. The antibody having this technical solution is named “LY-2” in the present invention; or (2) SEQ ID NO.6 and SEQ ID NO.8. The antibody having this technical solution is named “LY-3” in the present invention; or (3) SEQ ID NO.10 and SEQ ID NO.12. The antibody having this technical solution is named "LY-7" in the present invention.

[0008] In a preferred embodiment, the polynucleotide sequence encoding the heavy chain constant region of the antibody is shown as SEQ ID NO.14, and the polynucleotide sequence encoding the light chain constant region of the antibody is shown as SEQ ID NO.16 (kappa chain) or SEQ ID NO.18 (lambda chain).

[0009] Third, the present invention also provides an expression vector containing a polynucleotide encoding the above-mentioned human broad-spectrum, high-neutralizing activity anti-novel coronavirus monoclonal antibody, the expression vector containing the above-mentioned polynucleotide encoding the heavy chain variable region of the antibody and the polynucleotide encoding the light chain variable region of the antibody. The vector can be a eukaryotic expression vector conventionally used in genetic engineering. In a specific embodiment of the present invention, the vector is IgH (heavy chain expression vector), Igκ (κ light chain expression vector), Igλ (λ light chain expression vector) (see Tiller et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning, J Immunol Methods. 2008 January 1; 329(1-2): 112–124., the present invention incorporates this prior art document into the specification of the present invention by reference).

[0010] Fourth, the present invention provides a host cell expressing the above-mentioned human broad-spectrum, high-neutralizing activity anti-new coronavirus monoclonal antibody, and the host cell contains the above-mentioned expression vector.

[0011] The host cell may be a eukaryotic host cell conventionally used in genetic engineering. In a specific embodiment of the present invention, the host cell is a 293F cell. Other conventional eukaryotic host cells in the art, such as CHO cells, may also be used in the implementation of the present invention.

[0012] Fifth, the present invention also provides an antibody composition, the composition comprising a first antibody and a second antibody, the amino acid sequences of the heavy chain variable region and the light chain variable region of the first antibody are shown as SEQ ID NO.1 and SEQ ID NO.3, respectively, and the amino acid sequences of the heavy chain variable region and the light chain variable region of the second antibody are shown as: (1) SEQ ID NO. 5 and SEQ ID NO. 7; or (2) SEQ ID NO.9 and SEQ ID NO.11.

[0013] In another optional embodiment, the composition contains a first antibody and a second antibody, the amino acid sequences of the heavy chain variable region and the light chain variable region of the first antibody are shown as SEQ ID NO.5 and SEQ ID NO.7, respectively, and the amino acid sequences of the heavy chain variable region and the light chain variable region of the second antibody are shown as SEQ ID NO.9 and SEQ ID NO.11, respectively.

[0014] Sixth, the present invention provides the use of the above-mentioned human broad-spectrum, high-neutralizing activity anti-new coronavirus monoclonal antibodies in the preparation of new coronavirus disease treatment and / or prevention drugs, and the antibodies can be prepared as clinical treatment drugs related to new coronavirus infection.

[0015] Finally, the present invention provides the use of the above-mentioned human broad-spectrum high-neutralizing activity anti-new coronavirus monoclonal antibody in the preparation of a new coronavirus detection reagent. The new coronavirus detection reagent is an immunoassay reagent based on antigen-antibody specific binding reaction, including but not limited to enzyme-linked immunosorbent assay, chemiluminescent immunoassay, and radioimmunoassay, and the test sample is an in vitro serum, secretion, excretion, biopsy specimen, etc., and can also be an in situ test.

[0016] The human broad-spectrum, high-neutralizing activity anti-novel coronavirus monoclonal antibodies provided by the present invention are obtained by screening through single B cell flow sorting-antibody gene amplification paired expression technology, have unique CDR regions, can specifically bind to SARS-CoV-2, and can effectively neutralize a variety of novel coronavirus variants currently prevalent internationally, specifically including: SARS-CoV-2 WT, OmicronBA.5, OmicronXBB.1.5, OmicronEG.5, OmicronJN.1, and OmicronKP.2. The IC50 of antibody LY-3 and LY-7 against the pseudoviruses of the above strains is less than 0.07 μg / mL; the IC50 of antibody LY-2 against pseudoviruses other than the above SARS-CoV-2WT strain is less than 0.05 μg / mL, and the IC50 of pseudovirus neutralization against SARS-CoV-2 WT is greater than 1.1 μg / mL. The above antibodies have significant broad-spectrum neutralization ability against multiple different representative strains of new coronaviruses worldwide. Therefore, the antibodies provided by the present invention can be used to prepare COVID-19 emergency prevention and / or treatment drugs, which are fully humanized, highly expressed, and have good stability, and are suitable for industrialization. In addition, the antibody can also be used to prepare SARS-CoV-2 virus detection reagents for detecting viral antigens and for discovering effective neutralizing antigen epitopes. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 . Schematic diagram of flow cytometry sorting of novel coronavirus RBD-specific B cells; Figure 2 .Results of neutralization ability of antibodies against pseudovirus. DETAILED DESCRIPTION

[0018] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are merely exemplary and do not constitute any limitation on the scope of protection defined by the claims of the present invention.

[0019] Example 1: Preparation of novel coronavirus RBD probe 1.1 The biotinylated 2019-nCoV RBD protein was purchased from ACROBiosystems Group with the following catalog numbers: XBB.1.5 RBD (Cat. No.: SPD-C82Q3), EG.5 RBD (Cat. No.: SPD-C82Q5).

[0020] 1.2 Fluorescence labeling of biotinylated 2019-nCoV RBD protein The XBB.1.5 RBD probe protein was fluorescently labeled with PE (phycoerythrin), and the EG.5 RBD probe protein was fluorescently labeled with APC (allophycocyanin) for use in single-cell flow cytometry sorting.

[0021] Example 2: Screening and identification of human anti-SARS-CoV-2 broad-spectrum neutralizing monoclonal antibodies 2.1 Prepare cell lysis buffer: 20 μl cell lysis buffer per well, including 0.5 μl RNase-free, 5 μl 5× First Strand buffer, 1.25 μL 0.1M DTT, 0.0625 μl Igepal, 13.1875 μl water, cover with sealing film, and place in a 4°C refrigerator for use.

[0022] 2.2 Sample preparation: (1) Cell recovery of PBMCs from patients who recovered from novel coronavirus infection: After taking out the frozen cell tube from liquid nitrogen, quickly place it in a 37°C water bath. When it melts to an ice core, take it out, open it in a biosafety cabinet, and slowly drip RPMI-1640 (10% FBS) culture medium containing Benzonase (5 mL culture medium is used for 1 cell). Centrifuge at 1500 rpm for 10 minutes, discard the supernatant, suspend the cells with the residual liquid, add 10 mL of the above culture medium, mix well, take 50 μl for cell counting, and centrifuge at 1500 rpm for 10 minutes; adjust the cell concentration: discard the supernatant, suspend the cells with the residual liquid, adjust the cell concentration with the above culture medium, and add 2.5×10 6 cells / well; (2) Prepare 2 mM EDTA / PBS solution, hereinafter referred to as E-PBS; (3) Place the 96-well cell plate in a centrifuge and centrifuge at 4°C, 2000 rpm for 3 minutes, and discard the supernatant (operate in a biosafety cabinet, with paper towels placed on the high pressure table); (4) Add 50 μl of Vivid working solution to each well (prepare Vivid (UV) working solution: dilute with PBS at 1:1000 and mix well), mix well, and incubate on ice for 20 minutes in a dark place. (5) Add 150 μl of E-PBS to each well and centrifuge at 2000 rpm for 3 minutes at 4 °C. (6) Discard the supernatant and add 50 μl of extracellular antibody mixture (2 μl CD3-Pacific Blue, 2 μl CD8-Pacific Blue, 1.5 μl CD14-Pacific Blue, 1 μl CD19-BV510, 2 μl CD20-ECD, 2.5 μl CD27-APCCy7, 5 μl IgG-FITC, 2.5 μl IgM-PercpCy5.5, 2.5 μl PD-1-PECy7, 1 μl CXCR5-APC-R700, 5 μl CXCR3-PECy5, 1 μl CD45RA-BV650, 1 μl CD4-BV605, 5 μl XBB-RBD-PE, 5 μl EG.5-RBD-APC, 11 μl E-PBS), mix well, and incubate on ice for 60 min in the dark. (7) Add 150 μL of E-PBS to each well, centrifuge at 2000 rpm for 3 minutes at 4 °C, and discard the supernatant; (8) Add 200 μL of E-PBS to each well, centrifuge at 2000 rpm for 3 minutes at 4 °C, and discard the supernatant; (9) Add 200 μL of E-PBS to each well, mix well, filter the cell suspension of the same sample into the same flow-through tube, and store at 4°C in the dark for sorting; (10) Single-stained tube control: set up 1 unstained tube control (1 drop of compensation microspheres in 200 μl E-PBS) and 15 single-stained tubes (1 drop of compensation microspheres in each tube, 2 μl CD3-Pacific Blue, 2 μl CD8-PacificBlue, 1.5 μl CD14-Pacific Blue, 1 μl CD19-BV510, 2 μl CD20-ECD, 2.5 μl CD27-APCCy7, 5 μl IgG-FITC, 2.5 μl IgM-PercpCy5.5, 2.5 μl PD-1-PECy7, 1 μl CXCR5-APC-R700, 5 μl CXCR3-PECy5, 1 μl CD45RA-BV650, 1 μl CD4-BV605, 50 μl UV working solution), mix well, incubate on ice in the dark for 20 min, and then add 150 μl of E-PBS, centrifuge at 2000 rpm for 3 minutes at 4°C, discard the supernatant, and resuspend in 200 μl E-PBS.

[0023] 2.3 Flow cytometry sorting of single B cells: selection of CD3 - CD8 - CD14 - CD19 + CD20 + CD27 + IgG + IgM - RBD + The cells were sorted, and a total of 254 cells were sorted. First, single lymphocytes were identified, and then CD3 - Live cells of CD8-CD14- were used to exclude T cells and macrophages, and CD19 + CD20 + B cells, and then identify CD27 + Memory B cells, then circle out IgG + IgM - Finally, circle the memory B cells that bind to the probe RBD. These B cells are sorted into a 96-well plate containing the following lysis buffer system (Table 1). After sorting, immediately seal the 96-well plate with a sealing film, freeze it on dry ice, and then transfer it to a -80℃ refrigerator overnight. Perform PCR the next day. Results: The results of flow sorting are as follows Figure 1 shown.

[0024] Table 1. B cell lysis buffer system

[0025] 2.4 Amplification of fully human antibody variable region genes using RT-PCR technology The RT-PCR reaction system was configured as shown in Table 2, and 6 μl was added to each well for RT-PCR reaction.

[0026] Table 2. RT-PCR reaction system

[0027] The RT-PCR reaction program was set as follows: 42°C for 10 min, 25°C for 10 min, 50°C for 50 min, and 94°C for 5 min. After the reaction, 25 μl / well of water was added and the cells were stored at 4°C.

[0028] Two rounds of PCR reactions were performed, and the reaction technical parameters were as follows.

[0029] Table 3. First round PCR reaction system

[0030] Table 4. Primer sequences for the first round of PCR amplification

[0031] Table 5. Target fragments amplified by primers in the first round of PCR

[0032] Table 6. First round PCR program

[0033] After the first round of PCR reaction, a second round of PCR reaction was performed. The technical parameters of the second round of PCR reaction are shown below.

[0034] Table 7. Second round PCR reaction system

[0035] Table 8. Second round PCR primer sequences

[0036] Table 9. Target fragments amplified by the second round of PCR primers

[0037] Table 10. Second round PCR program

[0038] (2) Electrophoresis, sequencing, and pedigree analysis The second-round PCR products were detected by electrophoresis, and the heavy and light chain products were directly sequenced. The sequencing results were analyzed using the Antibody Family Gene Database (http: / / www.imgt.org / IMGT_vquest / vquest), and antibody variable region sequences with restriction sites were designed and synthesized (heavy chain: 5′-Age I, 3′-Sal I; Kappa chain: 5′-Age I, 3′-BsiW I; Lambda chain: 5′-Age I, 3′-Xho I). A total of 78 pairs of heavy and light chain paired clones were obtained.

[0039] 2.5 Construction of monoclonal antibody expression vector and plasmid transformation The synthesized gene was digested with the corresponding enzyme and recovered by gel electrophoresis again. The variable region gene was connected with the corresponding vectors IgH (heavy chain expression vector), Igκ (κ light chain expression vector), and Igλ (λ light chain expression vector) (see Tiller et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning, J Immunol Methods. 2008 January 1; 329(1-2): 112–124., which is incorporated into the specification of the present invention by reference) on a 16°C connector overnight. Then, plasmid transformation was performed, and 10 μL of the ligation product was added to 50 μL of DH5α competent cells, shaken and mixed, ice-bathed for 30 minutes, and heat-shocked in a 42°C water bath for 45 seconds. After the centrifuge tube was placed in an ice bath for 2 minutes, 1 mL of LB medium without resistance was added, and the culture was shaken at 37°C, 200 rpm for 1 hour. The residual bacterial liquid was spread on the LB plate with the corresponding resistance. Inverted culture was carried out at 37°C for 14-16 hours. A single clone colony was picked and inoculated into the LB liquid medium with the corresponding resistance. After shaking culture at 37°C, 200 rpm for 14-16 hours, plasmid extraction was performed (Omega's Plasmid Midi Kit).

[0040] 2.6 Antibody expression and purification The concentration of 293F cells was adjusted to 1.2 × 10 6 / ml, culture for 2 hours. Prepare solution A: add 50 μg antibody heavy chain DNA and 50 μg antibody light chain DNA to 2.5 mL of opti-MEM, and solution B: add 0.5 mL of PEI transfection reagent to 2.5 mL of opti-MEM and let stand for 5 minutes. Mix solution A and solution B, let stand for 20 minutes, add dropwise to 100 mL of 293F cell suspension, shake while dropping, and place at 8% CO2, 37°C, shake and culture for 5 days.

[0041] The antibody was purified using a Protein A affinity column (GE Health). The antibody concentration was determined using a NanoDrop2000 ultra-micro spectrophotometer (Thermo) and placed at 4°C for detection. In this step, 14 antibodies (antibody amount>1mg, antibody concentration>1000 μg / mL) were expressed from the 16 selected light / heavy chain paired antibodies.

[0042] Example 3 Neutralization activity assay of antibodies against SARS-CoV-2 pseudovirus 3.1 Pseudovirus packaging: The full-length S protein gene of artificially synthesized SARS-CoV-2 (GenBank: MN908947) was inserted into the pcDNA3.1 expression plasmid to construct pcDNA-SARS-CoV-2-S. The mutation sites of the pseudovirus with mutations are shown in Table 11 and introduced into the S gene.

[0043] Table 11. Pseudovirus mutation sites

[0044] 3×10 6 (3 million) 293T / 17 cells were inoculated in T75 cell culture flasks and cultured at 37°C with 5% CO2 for 20-24 hours. Fugene 6 Transfection Reagent (Promega, Cat#E2691) was used for transfection: 30 μg of plasmid pcDNA-SARS-CoV-2-S was transfected into 293T cells in T75 culture flasks, and 1.05×10 6 293T cells were infected with G*ΔG-VSV virus at TCID50, and the culture medium was replaced after 8 hours. 24 hours after transfection, the culture supernatant was collected and filtered to obtain pseudovirus of SARS-CoV-2 S protein, and then stored at -80℃.

[0045] 3.2 Neutralization experiment: In a 96-well plate, 100 μL of serially diluted antibody dilutions were added to each well, and then the pseudovirus was diluted to 1.3×10 4TCID50 / mL, add 50 μL to each well of columns 3-11, so that the amount of pseudovirus added is 650TCID50 / well. Place the above 96-well plate in a cell culture incubator (37°C, 5% CO2) and incubate for 1 hour. When the incubation time reaches half an hour, take out the prepared Vero cells, discard the culture medium, add PBS buffer to wash the cells, discard PBS, add trypsin-EDTA digestion and centrifugation, add complete culture medium to resuspend the cells, and count the cells. Dilute the cell suspension to 2×10 5 Incubate for 1 hour, add 100 μL of cells to each well of the 96-well plate, so that each well contains 2×10 Vero cells. 4 . Gently shake the 96-well plate back and forth and left and right to evenly disperse the cells in the wells, and place the 96-well plate in a cell culture incubator and culture at 37°C and 5% CO2 for 28 hours. Remove the 96-well plate from the cell culture incubator, use a multichannel pipette to remove 150 μL of supernatant from each well, then add 100 μL of luciferase detection reagent and react at room temperature in the dark for 2 minutes. After the reaction is completed, shake and mix on a plate shaker, and place it in a multi-function plate reader to read the luminescence value. Calculate the neutralization inhibition rate: Calculate the IC50 of the antibody based on the neutralization inhibition rate results.

[0046]

[0047] From the tested antibodies, we screened out 3 antibodies with high neutralizing ability against the new coronavirus WT, OmicronBA.5, OmicronXBB.1.5, OmicronEG.5, OmicronJN.1, and OmicronKP.2, namely LY-2, LY-3, and LY-7. The detailed neutralization results of the monoclonal antibodies are shown in Figure 2 . Antibodies LY-3 and LY-7 have IC50 values ​​for pseudovirus neutralization against the above strains of the virus, which are less than 0.07 μg / mL, and IC50 values ​​for pseudovirus neutralization against OmicronKP.2 are less than 0.01 μg / mL, showing strong neutralizing activity against multiple variants of the novel coronavirus. Antibody LY-2 has IC50 values ​​for pseudovirus neutralization other than the above SARS-CoV-2 WT strain, which are less than 0.05 μg / mL, and IC50 values ​​for pseudovirus neutralization against SARS-CoV-2 WT are greater than 1.1μg / mL. The above antibodies have significant broad-spectrum neutralizing ability against multiple representative strains of the novel coronavirus worldwide.

[0048] Example 4: Antigen-antibody affinity kinetics determination The affinity of monoclonal antibodies was detected by BLI technology using the Octet Red 96 system (Fortebio, USA) and streptavidin sensor. The biotinylated novel coronavirus RBD protein used was purchased from ACROBiosystems Group, with the following catalog numbers: WT RBD (Cat. No.: SPD-C82E9), XBB.1.5 RBD (Cat. No.: SPD-C82Q3), EG.5 RBD (Cat. No.: SPD-C82Q5), and the homemade JN.1 RBD (319-537) sequence is shown in Table 11. The biotinylated SARS-CoV-2 RBD was diluted to a concentration of 2 μg / mL with PBST (PBS containing 0.02% Tween 20 and 0.1% bovine serum albumin) and then fixed to a streptavidin biosensor (Sartorius AG, Germany) for 60 seconds. After a 60-second washing step with PBST, the biosensor probe was immersed in a well containing serially diluted antibodies (200nM, 100nM, 50nM, 25nM, 12.5nM, 6.25nM, and 3.125nM) and bound for 120 seconds, followed by a 300-second dissociation step. The KD value was calculated using a 1:1 binding model in the data analysis software 12.2. The affinity constants (KD) of the three monoclonal antibodies to the SARS-CoV-2 RBD are shown in Table 12. Most KD values ​​are <0.001 nM (0.001 nM is the lower limit of affinity determined by BLI technology), and the KD values ​​are all <1.6 nM, indicating that these three antibodies have extremely strong affinity for the SARS-CoV-2 RBD.

[0049] Table 12. Antibody Affinity

[0050] The present invention screened 3 novel coronavirus monoclonal antibodies, sequenced the gene amplification products of their heavy and light chains, and obtained the gene coding sequences and amino acid sequences of the heavy and light chains of the antibodies as follows: The nucleotide sequence of the heavy chain variable region of the LY-2 antibody is shown in SEQ ID NO.2, the amino acid sequence is shown in SEQ ID NO.1, and the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in amino acids 26-35, 53-59 and 98-112 of SEQ ID NO.1; the nucleotide sequence of the light chain variable region is shown in SEQ ID NO.4, the amino acid sequence is shown in SEQ ID NO.3, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are shown in amino acids 26-34, 52-54 and 91-103 of SEQ ID NO.3. The amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.13, the nucleic acid sequence of the heavy chain constant region is shown in SEQ ID NO.14, the light chain of the LY-2 antibody is a lamda chain, the amino acid sequence is shown in SEQ ID NO.17, and the nucleic acid sequence of the light chain constant region is shown in SEQ ID NO.18.

[0051] The nucleotide sequence of the heavy chain variable region of the LY-3 antibody is shown in SEQ ID NO.6, the amino acid sequence is shown in SEQ ID NO.5, and the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in amino acids 26-33, 51-57 and 96-106 of SEQ ID NO.5; the nucleotide sequence of the light chain variable region is shown in SEQ ID NO. 8, the amino acid sequence is shown in SEQ ID NO.7, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are shown in amino acids 27-32, 50-52 and 89-96 of SEQ ID NO.7. The amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.13, the nucleic acid sequence of the heavy chain constant region is shown in SEQ ID NO.14, the light chain of the LY-3 antibody is a kappa chain, the amino acid sequence is shown in SEQ ID NO.15, and the nucleic acid sequence of the light chain constant region is shown in SEQ ID NO.16.

[0052] The nucleotide sequence of the heavy chain variable region of LY-7 is shown in SEQ ID NO.10, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.9, wherein the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in amino acids 26-35, 53-59 and 98-111 of SEQ ID NO.9, respectively; the nucleotide sequence of the light chain variable region is shown in SEQ ID NO.12, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.11, wherein the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are shown in amino acids 27-32, 50-52 and 89-95 of SEQ ID NO.11, respectively. The amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.13, and the nucleic acid sequence of the heavy chain constant region is shown in SEQ ID NO.14. The light chain of the LY-7 antibody is a kappa chain, and the amino acid sequence is shown in SEQ ID NO.15, and the nucleic acid sequence of the light chain constant region is shown in SEQ ID NO.16.

Claims

1. A humanized anti-novel coronavirus monoclonal antibody, characterized in that: The amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region and CDR1, CDR2 and CDR3 of the light chain variable region of the antibody are shown below: (1) positions 26-35, 53-59 and 98-112 of SEQ ID NO.1 and positions 26-34, 52-54 and 91-103 of SEQ ID NO.3; or (2) positions 26-33, 51-57 and 96-106 of SEQ ID NO.5 and positions 27-32, 50-52 and 89-96 of SEQ ID NO.7; or (3) Positions 26-35, 53-59 and 98-111 of SEQ ID NO.9 and positions 27-32, 50-52 and 89-95 of SEQ ID NO.

11.

2. The humanized anti-novel coronavirus monoclonal antibody according to claim 1, characterized in that: The amino acid sequences of the heavy chain variable region and the light chain variable region of the human anti-novel coronavirus monoclonal antibody are as follows: (1) SEQ ID NO.1 and SEQ ID NO.3; or (2) SEQ ID NO. 5 and SEQ ID NO. 7; or (3) SEQ ID NO.9 and SEQ ID NO.

11.

3. The humanized anti-novel coronavirus monoclonal antibody according to claim 2, characterized in that: The amino acid sequence of the heavy chain constant region of the human anti-novel coronavirus monoclonal antibody is shown in SEQ ID NO.13, and the amino acid sequence of the light chain constant region is shown in SEQ ID NO.15 or SEQ ID NO.

17.

4. A polynucleotide encoding the human anti-novel coronavirus monoclonal antibody according to claim 2 or 3, characterized in that: The polynucleotide sequences encoding the heavy chain variable region and the polynucleotide sequences encoding the light chain variable region of the human anti-novel coronavirus monoclonal antibody are as follows: (1) SEQ ID NO. 2 and SEQ ID NO. 4; or (2) SEQ ID NO. 6 and SEQ ID NO. 8; or (3) SEQ ID NO. 10 and SEQ ID NO.

12.

5. The polynucleotide encoding the human anti-novel coronavirus monoclonal antibody according to claim 4, characterized in that: The polynucleotide sequence encoding the heavy chain constant region of the human anti-novel coronavirus monoclonal antibody is shown in SEQ ID NO.14, and the polynucleotide sequence encoding the light chain constant region is shown in SEQ ID NO.16 or SEQ ID NO.

18.

6. An expression vector containing a polynucleotide encoding the humanized anti-novel coronavirus monoclonal antibody according to claim 2 or 3, characterized in that: The expression vector contains the polynucleotide encoding the heavy chain variable region of the human anti-novel coronavirus monoclonal antibody as described in claim 4 and the polynucleotide encoding the light chain variable region of the human anti-novel coronavirus monoclonal antibody.

7. A host cell containing the expression vector according to claim 6.

8. The host cell according to claim 7, characterized in that The host cell is 293F cell.

9. An antibody composition, characterized in that: The composition comprises a first antibody and a second antibody, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of the first antibody are shown as SEQ ID NO.1 and SEQ ID NO.3, respectively, and the amino acid sequences of the heavy chain variable region and the light chain variable region of the second antibody are shown as follows: (1) SEQ ID NO. 5 and SEQ ID NO. 7; or (2) SEQ ID NO.9 and SEQ ID NO.

11.

10. An antibody composition, characterized in that: The composition contains a first antibody and a second antibody, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of the first antibody are shown as SEQ ID NO.5 and SEQ ID NO.7, respectively, and the amino acid sequences of the heavy chain variable region and the light chain variable region of the second antibody are shown as SEQ ID NO.9 and SEQ ID NO.11, respectively.

11. Use of the human anti-novel coronavirus monoclonal antibody according to any one of claims 1 to 3 in the preparation of drugs for the treatment and / or prevention of novel coronavirus disease.

12. Use of the human anti-novel coronavirus monoclonal antibody according to any one of claims 1 to 3 in the preparation of novel coronavirus detection reagents.

Citation Information

Patent Citations

  • Humanized high-neutralizing-activity monoclonal antibody against novel coronavirus and application of humanized high-neutralizing-activity monoclonal antibody

    CN116675766A

  • Humanized Anti-covid-19 monoclonal antibody having high neutralization activity, and use thereof

    WO2023011147A1

  • Fully human broad-spectrum high-neutralizing-activity monoclonal antibody against SARS-cov-2 and use thereof

    WO2023040627A1

  • Human antibodies and antibody combinations for synergistic neutralization of SARS-cov-2, and use thereof

    WO2023102692A1

Cited By

  • Neutralizing antibody GR39 for resisting novel coronavirus SARS-CoV-2 and variant and application of neutralizing antibody GR39

    CN120842372A